Clinical Trials Browser

Active not recruiting × Solid Tumor × Clear all

NCT06166836 2026-03-25

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT06487858 2026-03-18

A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05162755 2026-03-13

S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT07450560 2026-03-10

Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET

Active not recruiting

Other solid neoplasm

Solid Tumor

NCT03207672 2026-03-03

Study of E7389 Liposomal Formulation in Participants With Solid Tumor

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05840224 2026-01-28

Study of GS-4528 in Adults With Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT06932952 2026-01-16

A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT03875287 2026-01-12

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT06631079 2026-01-08

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT06220318 2025-11-28

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05119907 2025-11-17

Study of Sacituzumab Govitecan in Patients With Solid Tumor

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05627063 2025-10-20

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05642780 2025-10-14

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05718557 2025-08-03

Study of PYX-106 in Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT02608385 2025-06-08

Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05379946 2025-04-08

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05580991 2025-02-13

Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT03839342 2025-02-03

BEAVER

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT04185831 2024-08-22

MEGALiT

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT03865082 2022-02-17

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor